Dalim BioTech Co., Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Seoul Korea, Republic of (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2013
NCT01780051
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

liothyronine (cytomel) (2 trials)

Drugs in Phase 1 Trials (2)

repaglinide (prandin) (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 2 (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3